Answers are grounded in this paper and cite their sources.
Review highlights indications and adverse effects of anti-TNFα biologics in juvenile idiopathic arthritis, indicating transformed outcomes for pediatric patients.
Juvenile Idiopathic Arthritis (JIA) encompasses a group of diseases of unknown etiology having in common arthritis in at least 1 joint that persists for 6 weeks and begins before 16 years of age, with other conditions excluded. With a prevalence of 1 per 1,000 children in the USA, JIA is the most common pediatric rheumatic illness and a major cause of acquired childhood disability. During the last 20 years, the advent of host immune response modifiers known as biologic agents, in particular the anti-TNFα agents (etanercept, infliximab, adalimumab), which directly inhibit the action of pro-inflammatory mediators, has revolutionized the treatment and the expected outcome of JIA. This article highlights treatment indications of anti-TNFα drugs and their more frequent side effects in JIA patients.
No takes yet. Share an insight, caveat, or question.
Taddio et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: